Cognitive Impairment in Older Adults With Hematologic Malignancies
Prevalence of Cognitive Impairment and Its Association With Activities of Daily Living Among Older Adults With Hematologic Malignancies Receiving Chemotherapy
This cross-sectional study aims to determine the prevalence of cognitive impairment and evaluate its relationship with activities of daily living among older adults with hematologic malignancies receiving chemotherapy.
研究概览
详细说明
Cognitive impairment is common among older adults with cancer and may affect treatment adherence and independence. This observational study will include adults aged 65 years or older with confirmed hematologic malignancies who are currently receiving chemotherapy.
Participants will undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) and functional assessment using the Katz Index of Activities of Daily Living (ADL) and Lawton Instrumental Activities of Daily Living (IADL).
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Kholoud K Fawzy, Resident
- 电话号码：01009850621
- 邮箱：khloud.18313604@med.aun.edu.eg
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.
描述
Inclusion Criteria:
- - Age 65 years or older
- Confirmed diagnosis of hematologic malignancy
- Currently receiving chemotherapy
- Able to communicate and participate in cognitive assessment
- Written informed consent
Exclusion Criteria:
- - Previously diagnosed dementia before the diagnosis of malignancy
- Delirium at the time of assessment
- Severe visual or hearing impairment interfering with cognitive testing
- History of major neurological disorders affecting cognition
- Severe psychiatric illness affecting cognitive assessment
- Critically ill patients unable to complete study assessment
学习计划
研究是如何设计的？
设计细节
- 观测模型：CASE_ONLY
- 时间观点：CROSS_SECTIONAL
队列和干预
团体/队列 |
|---|
|
Single cohort: Older adults with hematologic malignancies
Adults aged 65 years or older with hematologic malignancies receiving chemotherapy who will undergo cognitive and functional assessment. |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Prevalence of cognitive impairment
大体时间：Baseline
|
Proportion of participants with cognitive impairment defined as a Montreal Cognitive Assessment (MoCA) score less than 26. |
Baseline
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean MoCA score
大体时间：Baseline
|
Mean Montreal Cognitive Assessment (MoCA) score (range 0-30, higher scores indicate better cognition).. |
Baseline
|
|
Mean Katz ADL score
大体时间：Baseline
|
Mean Katz Index of Independence in Activities of Daily Living score (range 0-6, higher scores indicate greater independence). |
Baseline
|
|
Mean Lawton IADL score
大体时间：Baseline
|
Mean Lawton Instrumental Activities of Daily Living score (range 0-8, higher scores indicate greater independence) |
Baseline
|
|
Proportion with impaired activities of daily living
大体时间：Baseline
|
Proportion of participants with impaired Katz ADL score. |
Baseline
|
|
Proportion with impaired instrumental activities of daily living
大体时间：Baseline
|
Proportion of participants with impaired Lawton IADL score. |
Baseline
|
合作者和调查者
调查人员
- 学习椅：Soher M kasem, prof、Internal Medicine Department, Assiut University Hospitals
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.